Navigation Links
InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
Date:6/10/2009

tion of the nonclinical profile of INT131 into the clinic is an exciting validation of the selective PPAR modulator design of the molecule," added Dr Linda Higgins, Chief Scientific Officer of InteKrin Therapeutics. "INT131 retains or exceeds TZD potency and efficacy for glycemic lowering in rodent models of T2DM, while also showing remarkable safety in nonclinical studies of INT131 even at multiples of clinical exposures that far exceed those at which toxicities are observed with TZDs."

These Phase 2a study data provided the rationale for a double blind placebo controlled 24 week Phase 2b study of 4 doses of INT131 and 45 mg Actos(R) as active comparator in 360 T2DM patients. InteKrin completed enrollment of the study in March, 2009.

About INT131

INT131 is a next-generation, non-TZD insulin sensitizer and selective modulator of PPARgamma (SPPARM). INT131 belongs to a unique, non-TZD chemical class, and was purposely designed to retain the well validated and robust insulin sensitizing efficacy of PPARgamma while minimizing the typical side effects seen with the full agonists TZDs Actos(R) and Avandia(R). PPARgamma activation treats insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, t
'/>"/>

SOURCE InteKrin Therapeutics Inc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. InteKrin Therapeutics Announces $20 Million Series C Financing
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. Arete Therapeutics Presents Positive Clinical and Preclinical Data for AR9281
4. Oxygen Biotherapeutics, Inc. Announces Private Placement Financing Agreement and Offer to Acquire Warrants
5. Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Incs. GCS-100 Molecule
6. Natura Therapeutics and USF receive NIH grant to study green tea compound for Alzheimers
7. Hyperion Therapeutics Announces Results of Phase I Study in Patients With Liver Cirrhosis
8. Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine
9. SXC Health Solutions announces agreements for pharmacy technology services with Prime Therapeutics LLC
10. Cephalon Acquires Controlling Interest in Arana Therapeutics
11. Cornerstone Therapeutics Announces Management Change
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015 AxoGen, Inc. (NASDAQ: AXGN), ... $1.6 billion peripheral nerve repair market, reported record revenue ... 31, 2015 compared to $3.14 million in the year-ago ... our proprietary portfolio of nerve repair products - ... Protector – and our solid sales execution delivered another ...
(Date:5/5/2015)... The global lab automation market is expected ... in 2014, at an estimated CAGR of 6.7% from ... market on the basis of equipment and software, application, ... basis of application, Lab Automation Market is classified into ... Drug discovery is a major application of the lab ...
(Date:5/5/2015)... 2015 Viverae®, a health management ... a leading multinational developer, manufacturer and marketer of ... vascular, urology, oncology and surgical specialty products, as ... The Vanguard Award recognizes outstanding achievement in the ... Viverae’s significant client base. , Viverae reviewed the ...
(Date:5/5/2015)... Dr. Patricia George knows all too well the debilitating ... hypertension specialist at the University of Pittsburgh Medical Center ... initial idea entered her mind for Team PHenomenal Hope. ... the 2010 PHA International Conference,” George recalled. “The speakers ... their climb up Mt. Kilimanjaro and I remember thinking ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 In a April ... The Herald-Times , the Missouri State Highway Patrol (MSHP) ... Methamphetamine production or use for the second year in a ... to the FBI, reported 1,469 incidents in 2014 alone, around ... only around 2% of the US Population calls Indiana home, ...
Breaking Medicine News(10 mins):Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 2Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 3Health News:AxoGen, Inc. Reports 58% Year-Over-Year Revenue Growth for the 2015 First Quarter 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 2Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 3Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 4Health News:Global Lab Automation Market Forecast to 2020: Research Based on Equipment & Software, Applications, Type of Automation and End Users 5Health News:Viverae® Honors C. R. Bard, Inc. with 2015 Vanguard Award 2Health News:World PH Day: Team PHenomenal Hope Races to Spread the Word about Pulmonary Hypertension 2Health News:A Forever Recovery Releases New Information on the Epidemic Rise Of Methamphetamine Abuse in Midwest America 2
... 17 Zargis Medical Corp., a spin-off from Siemens Corporate Research ... Corp. (Nasdaq: SPDE ), announced today it has received ... Signal X6(TM) device. Zargis also announced the delivery of seven ... Department of Defense medical facilities. , , Signal ...
... , CHICAGO, Sept. 17 Today, Scott Lee Cohen, ... statewide "Listening Tour." Cohen embarked on Monday, September 14, 2009 from his ... than 40 planned meetings with elected officials and community leaders throughout the ... include:, Winnebago County; Rockford, IL; ...
... ... Novartis Oncology was conducted independently for CURE magazine among 1,365 of its readers living with ... ... -- A new national survey shows that nearly one in three patients with rare cancers ...
... , PITTSBURGH, Sept. 17 ... solutions for individuals with speech, language and learning disabilities, today ... the Year award from Microsoft Corp. This award recognizes ... Microsoft software in their products. , , ...
... , , , , ... SMTS ) today reported net revenues of $12.5 million for the third quarter ... same period of 2008. For the nine months ended August 31, 2009, ... , U.S. net revenues increased 10 percent to $10.4 million from ...
... , OVERLAND PARK, Kan., Sept. 17 Sunlight Saunas(TM) ... of industry firsts, and announce the winner of its 10th Anniversary ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090917/CG77208 ) , , During its ... carbon heating technology to the market. Unlike conventional saunas that use ...
Cached Medicine News:Health News:Zargis Receives FDA Clearance for Signal X6 Telemedicine Device; OK Allows Delivery to US Army 2Health News:Cohen Launches Second Statewide Tour 2Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 2Health News:New Survey Highlights the Challenges of People Living with Rare Cancer 3Health News:DynaVox Mayer-Johnson Receives Microsoft Award 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 2Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 3Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 4Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 5Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 6Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 7Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 8Health News:Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009 9Health News:Sunlight Saunas Celebrates 10 Years of Industry Firsts, and Announces 10th Anniversary Sweepstakes Winner 2
(Date:5/5/2015)... -- IBM Watson Health (NYSE: IBM ) today announced ... leading cancer institutes to accelerate the ability of clinicians ... The institutes will apply Watson,s ... the ability to translate DNA insights, understand a person,s ... to personalize treatment options. The project is part of ...
(Date:5/5/2015)... 5, 2015 (Family Features) Which health screenings ... like most adults, monitoring your weight, cholesterol, and blood ... But what about vision care? Photo ... reach their 40s, they often start to notice small ... lives and job performance. Whether having difficulty reading a ...
(Date:5/5/2015)... and NIJMEGEN, the Netherlands ... medical device company developing lower esophageal sphincter (LES) ... long-term, 3-year, positive safety and efficacy results. The ... of both heartburn and regurgitation and the "gold-standard" ... test) with near-complete elimination of dependence on daily ...
Breaking Medicine Technology:Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 2Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 3Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 4Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 5Clinicians Tap Watson to Accelerate DNA Analysis and Inform Personalized Treatment Options for Patients 6Eye Care as You Age 2Eye Care as You Age 3Eye Care as You Age 4Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 2Excellent three year results of EndoStim therapy for severe reflux disease presented at the SAGES Annual Meeting in Nashville. 3
... CEO Yaacov Shoham today issued the following statement, ... and asked them to upgrade IDenta,s current tier. They are ... 1. Annual financial report (audited) for year 2011 ( ... Statement The files can be found at the ...
... Mass., April 26, 2012  Sensitech Inc., the global ... the International Air Transport Association (IATA) has deemed ... devices to be in compliance with the 53rd ... Provision (SP) 188 published by the United Nations.   ...
Cached Medicine Technology:International Drug & Explosives Detection Company IDenta Corp. Releases Information to OTC markets. 2Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA 2
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
Clip-On Glasses clip onto regular eyewear frames. Plano (nonprescription) only. Will not fit over high-plus or high-minus presciptions, or over glasses with thick frames. Black wire frames. Wt. 63 g....
... manufactures standard and custom shields and barriers for ... low level or high level radiation shielding, we ... pure lead, lead acrylic, lead glass, lead vinyl ... We can offer shielding from 1/32" thick to ...
Height-Adjustable Mobile X-ray Barrier lets you get close to your patient during special procedures like cardiac cath. 24"H x 36"W viewing panel shields the upper body of one or two people and swivel...
Medicine Products: